Advisory Committee for Therapeutics
The TREAT-NMD Advisory Committee for Therapeutics (TACT) is a unique multi-disciplinary group of international experts including: academic and industry drug development experts, representatives of patient foundations, and regulatory bodies. TACT takes on the challenge of evaluating the therapeutic potential of drugs to optimise their design and development and offers a comprehensive, confidential review.
TACT can address:
- Trial design.
- Drug formulation.
- Bioavailability and toxicology.
- Regulatory and marketing considerations.
- Recommendations including go-no-go milestones.
The TACT meets twice a year: once in the autumn and once in the spring. Industry applicants are asked to pay a contribution towards the meeting costs based on size of company. For academic groups working on treatments or platform technologies for Duchenne muscular dystrophy, CureDuchenne offers financial support to cover a portion of meeting costs as well as travel and accommodation.
The TACT process is independent of any funding stream, but applicants often use its reports to support funding applications. A TACT review is NOT an endorsement by TACT or TREAT-NMD that a drug has any particular status in terms of regulatory or funding potential.
TACT Terms of Reference
Upcoming Advisory Committee Meetings
Autumn 2023 - Online
FULL
- 29th September (RESERVED)
- 30th November (RESERVED)
- 1st December (RESERVED)
- 15th December (RESERVED)
Spring 2024, Amsterdam, Netherlands
LIMITED AVAILABILTY
19th April – 21st April, 2024 FULL
Autumn 2024, Boston, USA
November 1st – 3rd, 2024. Four places are currently available
Spring 2025, Location TBC
April 4th – 6th, 2025. Four places are currently available.